Little is known about age-dependent variation in outcomes of cervical cytology with modern technologies. This populationbased study evaluated age-dependent changes after routine implementation of ThinPrep and SurePath technology in two independent laboratories, and controlled for time trends in a third laboratory using manually read conventional cytology continually. Data were collected from the Danish National Health Care Registers. For each laboratory, we compared proportions of abnormal cytology defined as atypical squamous cells of undetermined significance or worse (ASCUS1) by age and technology phase. The study included 489,960 cytological samples with no recent abnormality from women aged 23-59 years, routinely screened between 1998 and 2007. Implementation of SurePath liquid-based cytology (LBC) was followed by an increase in abnormal cytology in women aged 23-29 years from 4.6 to 6.1%, relative proportion (RP): 1.31 [95% confidence interval (CI): 1.08-1.61], and a decrease in women aged 45-59 years from 2.9 to 2.0%, RP: 0.71 (95% CI: 0.60-0.83). Implementation of ThinPrep LBC was followed by a decrease in abnormal cytology both in women aged 23-29 years from 7.7 to 6.8%, RP: 0.89 (95% CI: 0.78-1.02) and in women aged 45-59 years from 3.4 to 1.0%, RP: 0.30 (95% CI: 0.24-0.37). With implementation of imaging-assisted reading, regardless of the brand of technology, the proportion of abnormality increased by around 30% in all age groups (range from 19 to 41%). In the laboratory with unchanged technology no trends in abnormality proportions were observed. The impact of LBC implementation on cytological abnormality proportions varied considerably across age groups.Liquid-based cytology (LBC) and automation-assisted reading of cytological samples have been widely implemented in cervical screening. Little attention has been given in the literature to how cytological abnormality proportions change by age, as a consequence of implementing new cytological technologies. [1][2][3] It is reasonable to test for a potential effect by age, given that infections with human papillomavirus (HPV) and cervical abnormalities are age-dependent.The impact of new cytological technologies on the overall abnormality proportions has been well studied.2,4-8 Important changes in screening efficiency can, though, go unnoticed when the data have not been stratified accordingly. Changes in the abnormality rates in screening are not without an impact on both the women and the health care system.A recent Danish observational study, 9 based on 390,000 cytological samples from the Department of Pathology,